Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Yanhong Deng, Chao Wang et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 304
Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trialYi Cheng, Yanhong Deng, Zehua Wu et al.|EClinicalMedicine|2022Cited by 15
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch RepairHuabin Hu, Yanhong Deng, Zehua Wu et al.|Frontiers in Oncology|2020Cited by 12
mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trialCailu Shen, Yanhong Deng, Huabin Hu et al.|Annals of Translational Medicine|2022Cited by 9